Appropriate clinical use of darunavir 800 mg
The Southern African HIV Clinicians Society would like to update all HIV-treating clinicians with regard to the use of dolutegravir in women of childbearing potential (WOCP).
Palliative Care Guidelines for the Management of HIV-Infected People in South Africa
These updated guidelines provide healthcare providers with up-to-date information to support efforts to optimise safer conception care.
Two documents have been developed. The first provides a quick reference and summary of the main aspects related to supporting antiretroviral therapy adherence for HIV positive adolescents and young adults. The second, this expanded version, provides more detail for those requiring additional background information, resources and references.
This document provides a quick reference and summary of the main aspects related to supporting antiretroviral therapy adherence for HIV positive adolescents and young adults.
These guidelines are intended as an update to those published in the Southern African Journal of HIV Medicine in 2014 and the update on when to initiate antiretroviral therapy in 2015. Since the release of the previous guidelines, the scale-up of antiretroviral therapy (ART) in southern Africa has continued. New antiretroviral drugs have become available with improved efficacy, safety and more robustness. The guidelines are intended for countries in the southern African region, which vary between lower and middle income.
A supplement to the National HIV Testing Services Policy 2016.
The aim of the this PrEP guideline is to explain what PrEP is, outline current indications for its use, outline steps for appropriate user selection and provide guidance to monitor and maintain PrEP users.
This document is a corrigendum to our "Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update".
This guideline is an update of the post-exposure prophylaxis (PEP) guideline published by the Southern African HIV Clinicians Society in 2008.
These guidelines are an update of the Southern African HIV Clinicians Society’s ART 2014 guidelines. The update is to the section of the adult ART guidelines relating to when ART should be initiated.
UPDATED:Algorithms which assist in managing infants with indeterminate HIV PCR results.
Update to 2007 guidance to include all types of migrants and crisis-affected populations, including those forcibly displaced. This update stresses that migration and forced displacement must NO T be used as an excuse to deny treatment. Clear recommendations are provided for states, clinicians and programme managers, civil society, donors and United Nations (UN ) agencies.
2014 update to the Society guideline on adult antiretroviral therapy.
This document is provided as an information resource for all health care workers to assist in the appropriate prescribing of antibiotics.
Guideline on mental health disorders and CNS sequelae in HIV positive children and adolescents
A reference document to assist HIV nurse and doctor clinicians in managing mental health disorders
Practical guidance on the re-introduction of anti-TB drugs and ART in HIV/TB co-infected individuals presenting with DILI
Updated to include newly available drug formulations: ABC 60mg dispersible tablets and ABC (60mg) + 3TC (300mg) tablets
Update to 2007 guidelines on the prevention, diagnosis and management of cryptoccocal meningitis among HIV-infected persons
Guidance on how to switch patients from 3 separate antiretroviral (ARV) drugs to the new, single, FDC tablet containing tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV).
Recommendations for HIV resistance testing for people living with HIV in the southern African region
Guidelines include new data on antiretroviral (ARV) tolerability in the region and on new ARV drugs. Guidelines on third-line (or ‘salvage’) therapy have been expanded.
Interim guidance while abacavir/lamivudine, abacavir singles and lamivudine singles (2nd Line) are out of stock
Interim guidance while abacavir/lamivudine, abacavir singles and lamivudine singles are out of stock
If your facility is experiencing a lopinavir/ritonavir stock out then please follow this guidance.
Due to drug stock outs of tenofovir (TDF) and abacavir (ABC) across the country, the Society has developed some guidance for clinicians in order to ensure that no HIV infected South African currently on this treatment suffers because of these stock outs.